At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Open-label, Cross-over Study to Assess Lung Function and Patient Preference After a 4 Week Treatment Each With QVA149 vs. Tiotropium in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD) and Moderate to Severe Airflow Limitation Who Are on a Tiotropium Therapy (FAVOR Study)
In Brief
A Phase 4 clinical trial evaluating QVA149 and Tiotropium for Chronic Obstructive Pulmonary Disease and COPD. Completed, enrolled 88 participants across 18 sites.
Detailed Summary
The study is a multicenter, randomized, 2-period, open-label, two arm, cross-over study to show the superior effect of a 4 week treatment each with QVA149 versus tiotropium on lung function. Similarly, this study aims to evaluate patient preference after experiencing both treatment regimens in patients with a clinical diagnosis of COPD (GOLD 2013) and a moderate to severe airflow limitation who are symptomatic (defined as CAT score of at least 10) at screening despite being treated with tiotropium
Study Details
Timeline
Interventions
QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day